The Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer SPORE Biostatistics and Computational Biology Core (Core B) collaborates and provides consultation on all research activities within the SPORE, including SPORE Projects, Developmental Research Program and Career Development Program projects to ensure the highest standards of scientific rigor in areas of study design, data management and integrity and data analysis and interpretation. The overarching goal is to promote translational research derived from fundamental discoveries in the laboratory that can lead to tangible clinical benefit. In addition, we will collaborate with other SPORE Cores to create an integrated system of resource support for the SPORE and SPORE investigators. Core B will also provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers. Core B has a wealth of experienced biostatisticians and computational biologists equipped with excellent computational support, including major commercial and public-use statistical software, and a large library of locally written software for design and analysis.

Public Health Relevance

Organizing biostatistical and computational biology expertise as a shared resource core is a cost-effective approach to ensure that collaboration is readily available to SPORE investigators. Core B is effective in guaranteeing a high degree of quality of biostatistical support and integration across the SPORE, including Projects and Cores, which have interrelated analytic goals and needs, enhancing the SPORE?s ability to provide translational research outcomes with tangible clinical benefit.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127
Kensler, Kevin H; Beca, Francisco; Baker, Gabrielle M et al. (2018) Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. NPJ Breast Cancer 4:33
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Guerriero, Jennifer L (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med 24:472-489
Kuang, Yanan; Siddiqui, Bilal; Hu, Jiani et al. (2018) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Sun, Bowen; Wang, Geng; Liu, Huidong et al. (2018) Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget 9:23878-23889
Willis, Nicholas A; Panday, Arvind; Duffey, Erin E et al. (2018) Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLoS Genet 14:e1007486

Showing the most recent 10 out of 66 publications